The marketing authorization holder has informed its supplied customers in a letter dated 23.03.2018 that increased anaphylactic reactions have been reported after administration of an identical product in France. For this reason, the above mentioned batches are recalled as a precautionary measure.
|Name of the medicinal product
|Inutest 25 % Ampullen
|Marketing authorisation number(s)
|Marketing authorisation holder
|Fresenius Kabi Austria GmbH
|Classification of the recall
|BASG reference number